Reported about 10 hours ago
Gilead Sciences, Inc. (GILD) is expanding its U.S. manufacturing capabilities with a $32 billion investment aimed at enhancing its production of antiviral and oncology therapies through AI integration. The company has started construction on a 180,000-square-foot Technical Development Center in Foster City, California, which will utilize advanced technologies to improve biologics production and access to precision medicine. Additionally, Gilead plans to partner with PEPFAR to provide HIV prevention treatments to millions in developing countries, further solidifying its commitment to global health.
Source: YAHOO